Chemotherapy, Nausea, Vomiting
Conditions
Keywords
pediatrics, nausea, vomiting, chemotherapy, antiemetic
Brief summary
The primary objective of this study is to compare the absorption of a prepared aprepitant oral suspension with that of the aprepitant capsule in children being treated with chemotherapy agents that are likely to cause vomiting.
Detailed description
Antiemetic therapies have improved in recent years, but chemotherapy-induced nausea and vomiting (CINV) are still common and are among the most distressing side effects of chemotherapy. In a recent survey, parents of children receiving chemotherapy in Ontario centres identified nausea as the fourth most prevalent and bothersome treatment-related symptom experienced by their children. Aprepitant is commercially available in Canada as capsules. An oral liquid aprepitant formulation would be ideal for oral administration to children.
Interventions
DRUGOral Aprepitant
Subject will receive an oral suspension containing 125mg of Aprepitant
DRUGAprepitant
Subjects will receive a 125 mg Aprepitant capsule
Sponsors
The Hospital for Sick Children
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
12 Years to 18 Years
Healthy volunteers
No
Inclusion criteria
* 12-18 years of age; * able to swallow whole capsules; * weighing ≥40kg; * AST, ALT no more than 3 times the upper limit of normal for age and bilirubin concentrations within normal limits; * receiving 2 consecutive (within 8 weeks) eligible, though not necessarily identical, IV chemotherapy cycles; * English speaking (nausea assessment tool (PeNAT30) has been validated only in English) * cognitive ability of the child believed to be at least at a 4 year old level according to parent or health care professional (to permit self-assessment of nausea severity).
Exclusion criteria
* receiving very cisplatin containing chemotherapy (aprepitant capsule administration to these patients is the current standard of care at Sick Kids) * receiving chemotherapy within 5 days before,during or 5 days after either study cycle that is known or suspected to interact with aprepitant; that is, cyclophosphamide, doxorubicin, daunomycin, etoposide, irinotecan, ifosfamide, imatinib, paclitaxel, topotecan, vinorelbine, vinblastine and vincristine; * receiving medication known to interact with aprepitant other than dexamethasone (see Appendix I for list of applicable agents and timeframe for exclusion); * Pregnant or breastfeeding
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Bioavailability of the oral suspension relative to the capsule | 6 weeks |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Severity of chemotherapy-induced nausea and vomiting (CINV) | 6 weeks | Subject will be asked to record episodes of nausea and vomiting that occur during and immediately following each chemotherapy cycle studied |
| Proportion of children with adverse effects attributable to aprepitant | 6 weeks | — |
Countries
Canada
Outcome results
None listed